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Abstract
Introduction: Heparin-induced thrombocytopenia (HIT) is a serious, prothrombotic, immune-mediated adverse
reaction triggered by heparin therapy. When HIT is diagnosed or suspected, heparins should be discontinued, and
an alternative, fast-acting, parenteral, nonheparin anticoagulation such as argatroban should be initiated. Limited
and inconsistent data exist about dosing of argatroban in intensive care unit (ICU) patients with critical illnesses.
Methods: Retrospective analysis of 12 ICU patients with multiple organ dysfunction syndrome (MODS) treated with
argatroban for suspected or diagnosed HIT.
Results: The 12 ICU patients with a mean platelet count of 46,000 ± 30,310 had a mean APACHE II score of 26.7 ±
7.8 on ICU admission and a mean SAPS II score of 61.5 ± 16.3 on the first day of argatroban administration. A
mean argatroban starting dose of 0.32 ± 0.25 μg/kg/min (min, 0.04; max, 0.83) was used to achieve activated
partial thromboplastin times (aPTTs) >60 sec or aPTTs of 1.5 to 3 times the baseline aPTT. Adjustment to aPTT
required dose reduction in six (50%) patients. Patients were treated for a mean of 5.5 ± 3.3 days. The final mean
dose in these critically ill patients was 0.24 ± 0.16 μg/kg/min, which is about one eighth of the usually
recommended dose and even markedly lower than the previously suggested dose for critically ill ICU patients. In
all patients, desired levels of anticoagulation were achieved. The mean argatroban dose was significantly lower in
patients with hepatic insufficiency compared with patients without hepatic impairment (0.10 ± 0.06 μg/kg/min
versus 0.31 ± 0.14 μg/kg/min; P = 0.026). The mean argatroban dose was significantly correlated with serum
bilirubin (r = -0.739; P = 0.006).
Conclusions: ICU Patients with MODS and HIT can be effectively treated with argatroban. A decrease in the initial
dosage is mandatory in this patient population. Further studies are needed to investigate argatroban elimination
and dosage adjustments for critically ill patients.
Introduction
Heparin-induced thrombocytopenia (HIT) is a serious,
prothrombotic, immune-mediated adverse reaction trig-
gered by heparin therapy [1]. HIT is more often caused
by unfractionated heparin than by low-molecular-weight
heparin [2]. In HIT, antibodies of immunoglobulin G
class bind to a complex of heparin and platelet factor 4,
resulting in platelet activation and excessive thrombin
generation, leading to thrombocytopenia, a hypercoagu-
lable state, and often to thrombosis. Unless alternative
anticoagulation is initiated, the risk of arterial or venous
thromboembolic complications in HIT is about 30% to
75% of cases, leading to limb amputations in 10% to
20% and to death in 20% to 30% of cases [3-6]. If plate-
let count decreases to ≥50% or thrombosis occurs
between day 5 and 14 of heparin therapy, or both, HIT
should be suspected [7]. In patients with recent heparin
exposure within the previous 100 days, clinically signifi-
cant HIT antibodies may still circulate and can therefore
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any medium, provided the original work is properly cited.cause an abrupt decrease in platelet count with restart-
ing of heparin treatment [8].
For laboratory diagnosis of HIT antibodies, antigen
assays as well as functional assays (platelet activation)
are used, both showing a high sensitivity [7,9].
According to consensus guidelines, when HIT, with or
without thrombosis, is diagnosed or strongly suspected,
heparins should be immediately discontinued and
an alternative, fast-acting, parenteral, nonheparin anti-
coagulation should be promptly initiated [7]. Three
alternative parenteral anticoagulants have been approved
for use in HIT: the heparinoid danaparoid and the direct
thrombin inhibitors, lepirudin and argatroban.
Argatroban is a synthetic direct thrombin inhibitor,
derived from L-arginine, that selectively and reversibly
inhibits free and clot-bound thrombin at the catalytic
site [10]. Argatroban is predominantly hepatically meta-
bolized [11]. Renal elimination of argatroban is minimal,
and pharmacokinetic and pharmacodynamic parameters
of argatroban have been demonstrated to be comparable
between healthy subjects and non-HIT patients with dif-
ferent degrees of renal insufficiency [11-15]. In addition,
argatroban anticoagulation has been used successfully
during renal-replacement therapy in patients with and
without HIT [15,16]. However, recent limited data sug-
gested the consideration of kidney function before initia-
tion of argatroban therapy in HIT [13,17,18].
The recommendation for initial dosing of argatroban
in HIT is 2 μg/kg/min, adjusted as needed to achieve
activated partial thromboplastin times (aPTTs) of 1.5 to
3t i m e st h ep a t i e n t ’s baseline aPTT [5,19]. To account
for the reduction in clearance, the recommended initial
dose for patients with hepatic impairment is 0.5 μg/kg/
min.
Despite the availability of these recommendations,
limited and inconsistent data exist about dosing pat-
terns, efficacy, and safety of argatroban therapy in inten-
sive care unit (ICU) patients with critical illness or
multiple organ dysfunction syndrome (MODS). Studies
on argatroban therapy in critically ill patients with
MODS and suspected or diagnosed HIT are limited to
very small case series with conflicting results [13,14].
Previous data showed that no argatroban dose adjust-
ment is needed in acutely ill patients [20]. In contrast,
recent data indicated that the approved dosing regimens
of the direct thrombin inhibitors are too high in criti-
cally ill ICU patients, especially with MODS [14,17,21].
A commonly suggested starting dose for ICU patients is
0.5 to 1.0 μg/kg/min, with adjustment according to
aPTT (target range, 1.5 to 3 times or ≥60 sec)
[13,21,22]. Further investigations are needed to ensure
safe, appropriate dosing guidelines for the use of arga-
troban in the setting of critically ill ICU patients with
HIT.
In our retrospective analysis, we evaluated critically ill
ICU patients with MODS treated with argatroban for
diagnosed or suspected HIT. The primary objective of
this observational analysis was to demonstrate dosing-
adjustment difficulties of argatroban, especially in the
setting of MODS.
Materials and methods
We retrospectively analyzed argatroban dosing patterns
and anticoagulant responses in 12 consecutively selected
adult patients with MODS who received argatroban for
suspected or diagnosed HIT between March 2007 and
March 2009 at the general ICU of a German university
hospital (Klinikum rechts der Isar der Technischen
Universität München, Munich, Germany). The patients
were critically ill (defined as having an Acute Physiology
and Chronic Health Evaluation II Score, APACHE II,
higher than 15) and were treated for MODS involving
two or more organ systems. The APACHE II score was
calculated after admission of a patient to the ICU and,
in addition, the Simplified Acute Physiology Score
(SAPS II) was calculated on the first day of argatroban
administration.
The general policy in our ICU is to stop all sources of
heparin and initiate an alternative anticoagulant on rea-
s o n a b l es u s p i c i o no fH I T .T h ec h o i c eo fa l t e r n a t i v e
anticoagulant agent and initial dose is at the discretion
of the treating physician. The dose is generally adjusted
to achieve aPTTs >60 sec or aPTTs of 1.5 to 3 times
the baseline aPTT. HIT was defined as a decrease in
platelet count to >150 × 10
9/L or by >50%, starting at
least 5 days after initiation of heparin exposure, pro-
vided that a more likely cause for the platelet decline
has been ruled out. The aPTT was measured about 2 h
after initial argatroban administration, and dose adjust-
ments were made to maintain desired aPTT levels. The
aPTT was assessed daily and 4 h after any dose adjust-
ment. Data extracted from each patient chart included
the demographics, previous heparin exposure, organ-fail-
ure status, heparin-induced platelet-activation (HIPA)
test results (functional assay, platelet activation), each
argatroban dose, as well as aPTT and International
Normalized Ratio (INR) values.
A seriously reduced level of consciousness, Glasgow
coma scale <12 (without head injury) or Cook and
Palma score <12 was defined as cerebral involvement in
MODS. Respiratory insufficiency was defined as neces-
sity for noninvasive ventilation or mechanical ventila-
tion. Need for administration of inotropic substances or
vasopressors was documented as circulatory failure. A
patient was considered to have hepatic insufficiency if
the serum aspartate aminotransferase or alanine amino-
transferase levels thrice exceeded the upper limit of
normal. A patient was considered to have renal
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or the serum creatinine was >3.0 mg/dL, or both, or
renal replacement therapy was needed.
Descriptive statistical analyses were performed by
using Tinn-R statistical softw a r e .R e s u l t s ,w h e r ea p p l i -
cable, are reported as mean ± SD. To evaluate factors
associated with the individual mean argatroban dose, we
performed univariate analysis (Spearman correlation),
including serum bilirubin, aspartate aminotransferase,
Model of End-Stage Liver Disease (MELD) score,
APACHE II score, and serum creatinine. The Wilcoxon
test for unpaired measurements was applied to compare
the mean argatroban dose in patients with or without
hepatic or renal failure, respectively. Statistical signifi-
cance was defined as a P value of < 0.05. Factors signifi-
cantly correlated to the mean argatroban dose were
included in a multiple regression analysis (backward
selection) regarding the individual mean argatroban
dose in a second step. In addition to the factors derived
from Spearman correlation, a limited number of factors
with high ap r i o r iprobability of impact on the mean
argatroban dose (such as APACHE II score) and mar-
kers of hepatic and renal failure were included in the
multiple regression analysis. Statistical analysis was per-
formed by using software (SPSS. version 16; SPSS inc.,
Chicago, IL, USA). The study was approved by the local
ethics committee. The need for informed consent was
waived for this retrospective analysis of data.
Results
Patients
Twelve (eight female and four male) critically ill ICU
patients with a mean age of 70.0 ± 17.3 years and a
mean weight of 69.5 ± 20.1 kg were enrolled in this
study (Table 1). The mean APACHE II score on ICU
admission and the mean SAPS II score on the day of
initial argatroban administration were 26.7 ± 7.8 and
61.5 ± 16.3, respectively. All patients were treated for
MODS with an involvement of two or more organ sys-
tems (Table 2), and eight (67%) patients were classified
as having sepsis. Mechanical ventilation was needed in
10 (83%) patients, and administration of inotropic sub-
stances or vasopressors was necessary in seven (58%)
patients. Renal insufficiency was observed in seven
(58%) patients, and hepatic insufficiency in four (33%)
patients. Five (42%) patients died during their ICU stay.
Argatroban anticoagulation
All patients were treated with argatroban anticoagula-
tion for suspected HIT. When argatroban therapy was
started, mean thrombocyte count was 46,000 ± 30,310/
μl (min, 9,000; max, 93,000) (Table 3). In six (50%)
patients, suspicion of HIT was confirmed by laboratory
tests (functional assay, HIPA test). Argatroban anticoa-
gulation in this study was started at a low dose, and no
loading dose of argatroban was used: The mean argatro-
ban starting dose was 0.32 ± 0.25 μg/kg/min (min, 0.04
μg/kg/min; max, 0.83 μg/kg/min) to achieve aPTTs >60
sec or aPTTs of 1.5 to 3 times the baseline aPTT.
Desired levels of anticoagulation were achieved in all
patients. In the critically ill patients in this study, the
aPTT was elevated at baseline (median value of 49 ± 13
sec) and increased further (median of 66 ± 18 sec) by
the first assessment after initiating argatroban. In accor-
dance to that, baseline INR values increased from 1.23 ±
0.38 to 1.49 ± 0.23 after starting argatroban. Despite the
very low starting dose, adjustment to aPTT required
dose reduction in six (50%; one patient with renal and
hepatic failure, two patients with renal insufficiency, one
patient with hepatic impairment, two patients with
Table 1 Characteristics of patients, demographic parameters
Patient number Sex APACHE-II score SAPS-II score Main diagnosis ICU survival Cause of death
1 m 17 42 Cirrhosis of the liver - Pneumonia, sepsis
2 f 27 69 Pneumonia, sepsis +
3 f 31 78 Erysipelas, sepsis +
4 f 27 56 Liver failure - Pneumonia, sepsis
5 m 22 62 Intracerebral hemorrhage +
6 f 33 73 Pneumonia, sepsis - Peritonitis, sepsis
7 m 34 77 Pneumonia, sepsis +
8 f 17 44 Pneumonia, sepsis +
9 f 34 79 Pneumonia, sepsis - Pneumonia, sepsis
10 f 40 74 Pulmonary embolism - Heart insufficiency
11 f 19 54 Retroperitoneal hemorrhage +
12 m 19 30 Cirrhosis of the liver +
8 f/4 m 26.7 ± 7.8 61.5 ± 16.3 7+/5-
Showing sex (m, male; f, female), APACHE II score on ICU admission, SAPS-II score on the day of first argatroban administration, main diagnosis on ICU admission,
ICU survival (+, survived; -, died), and cause of death. Data are provided for each patient as mean ± SD where possible. APACHE II, Acute Physiology and Chronic
Health Evaluation II Score; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score.
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for a mean of 5.5 ± 3.3 days (min, 1 day; max, 11 days).
The final mean dose in these critically ill ICU patients
was 0.24 ± 0.16 μg/kg/min (min, 0.02 μg/kg/min; max,
0.48 μg/kg/min).
The mean argatroban dose was significantly different
in patients with hepatic insufficiency compared with
patients without hepatic impairment (0.10 ± 0.06 μg/kg/
min versus 0.31 ± 0.14 μg/kg/min; P = 0.026). In con-
trast, no difference was found in mean argatroban dose
in patients with or without renal insufficiency (0.23 ±
0.18 μg/kg/min versus 0.25 ± 0.14 μg/kg/min; P =
0.530).
Univariate analysis demonstrated that the mean arga-
troban dose was significantly correlated with serum
bilirubin (r = -0.739; P = 0.006) but not with aspartate
aminotransferase (r = -0.321; P = 0.309), MELD score
(r = -0.400; P = 0.600), APACHE II score (r =0 . 3 3 0 ;
P = 0.295) or serum creatinine (r = -0.198; P = 0.538).
Subsequently we performed multiple regression analysis
regarding mean argatroban dose, showing that among
all analyzed variables (APACHE II, serum creatinine,
presence of hepatic insufficiency, presence of renal
insufficiency), only the presence of hepatic insufficiency
was independently associated with the mean argatroban
dose (r = 0.676; P = 0.016).
Table 2 Characteristics of patients and organ dysfunction
Patient number CNS involvement Respiratory insufficiency Circulatory failure Renal insufficiency Hepatic insufficiency Sepsis
1 +- - + + +
2 ++ - - - +
3 ++ + + - +
4 ++ + - + +
5 ++ - - - -
6 ++ + + - +
7 ++ - + - +
8 ++ + - - -
9 ++ + + + +
10 ++ + + - +
11 ++ - - - -
12 +- - + + -
Total 12 10 6 7 4 8
Showing organ dysfunction and diagnosis of sepsis at the beginning of argatroban therapy. Data are provided for each patient.
Table 3 Argatroban therapy
Patient HIPA
test
Platelet count
(×1,000/μL)
INR before
A
INR after A aPTT before
A (sec)
aPTT after
A (sec)
aPTT mean during
A therapy (sec)
A starting dose
(μg/kg/min)
A mean dose
(μg/kg/min)
1 + 93 1.2 1.6 44 80 68.4 0.08 0.02
2 + 48 0.8 1.2 39 62 56.3 0.48 0.48
3 - 18 1.1 1.6 63 106 88.7 0.56 0.37
4 + 9 2.1 1.5 79 57 93.2 0.22 0.15
5 + 38 1.1 1.6 29 51 36.4 0.04 0.14
6 - 31 1.0 1.0 48 51 60.5 0.14 0.14
7 - 87 1.1 1.4 46 53 62.5 0.46 0.46
8 - 46 1.2 1.6 52 87 61.3 0.83 0.30
9 - 19 1.9 1.9 54 63 63.0 0.08 0.08
10 - 15 1.1 1.6 58 75 67.5 0.56 0.42
11 + 90 1.0 1.5 42 56 68.5 0.22 0.20
12 + 58 1.2 1.4 36 47 51.5 0.14 0.14
6+/6- 46 ± 30 1.23 ± 0.38 1.49 ± 0.23 49 ± 13 66 ± 18 64.8 ± 15.1 0.32 ± 0.25 0.24 ± 0.16
For each patient (pt), HIPA-test results (+, positive, - = negative), platelet count (×1,000 per microliter), INR/aPTT values before argatroban therapy, and INR/aPTT
values at first assessment after starting argatroban are provided. Mean aPTTs during argatroban therapy, argatroban starting doses, and argatroban mean doses
are shown. Data are provided for each patient and as mean ± SD where possible. A, argatroban; aPTT, activated partial thromboplastin time; HIPA, heparin-
induced platelet activation; INR, International Normalized Ratio.
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occurred in the patient population of this study during
anticoagulation therapy with argatroban. Furthermore,
no arterial or venous thromboembolic complications
appeared in the 12 patients treated with argatroban.
Discussion
In critically ill ICU patients, the recognition, diagnosis,
and therapy of HIT is very difficult. Thrombocytopenia
(mostly due to sepsis or hemodilution) is a very com-
mon laboratory finding, occurring in ~30% to 50% of
patients in the medical ICU [23]. However, the diagnosis
of HIT should be based on clinical considerations and
treatment should not be delayed, pending laboratory
confirmation [3,7]. On suspicion of HIT, all sources of
heparin should be eliminated and an alternative anticoa-
gulant must be initiated [7].
Three alternative parenteral anticoagulants have been
approved for treatment of HIT: the heparinoid danapar-
oid and the direct thrombin inhibitors lepirudin and
argatroban [5,24-26].
In the special setting of critically ill ICU patients, arga-
troban has some advantages over lepirudin [14]. Lepiru-
din is renally cleared and associated with an increased
elimination half-life and bleeding risk in renal failure
[27]. Argatroban is metabolized hepatically and elimi-
nated in the feces through biliary excretion [11]. Many
studies indicated that renal insufficiency does not influ-
ence pharmacokinetic or pharmacodynamic parameters
of argatroban and that argatroban is well tolerated and
provides adequate anticoagulation in patients with renal
dysfunction or failure as well as during renal replace-
ment therapy [11-14,16,28-30]. In contrast, recent lim-
ited data suggested consideration of kidney function and
dose adjustment in HIT therapy with argatroban
[13,16-18]. Moreover, the elimination half-life of arga-
troban (about 39 to 51 min in healthy subjects) is
reduced by 50% in comparison to lepirudin [11].
Two prospective, multicenter, historical controlled
studies and reanalyses of their combined data demon-
strated that the use of argatroban resulted in reducing
the composite end point of death, amputation, or new
thrombosis in HIT patients, with particular benefit in
decreasing new thrombosis without increasing bleeding
[5,19].
The recommended initial dose of argatroban for the
prophylaxis or treatment of thrombosis in HIT is 2 μg/
kg/min (0.5 μg/kg/min for patients with hepatic impair-
ment) with following adjustment to aPTTs of 1.5 to 3
times the baseline aPTT [5,19].
Very limited and inconsistent data exist about dosing
patterns of argatroban therapy in ICU patients with cri-
tical illness [13,14]. Some data demonstrate that no dose
adjustment is required in argatroban therapy of acutely
ill patients [20]. Other data indicate that the pharmaco-
kinetics and clearance of argatroban seem to be substan-
tially altered in critically ill patients [13,14,17,21,31,32].
Especially in the setting of sepsis and MODS, hepatic
clearance of argatroban may be significantly reduced.
Hepatic metabolism in these patients may be influenced
by reduced cardiac output, circulatory distributory fail-
ure, and/or disseminated intravascular coagulation,
resulting in decreased hepatic perfusion. Therefore,
some authors suggest an argatroban starting dose for
ICU patients of 0.5 to 1.0 μg/kg/min [13,21,22].
To gain additional knowledge about dosing-adjust-
ment problems in the use of argatroban in the setting of
critical illness and HIT, we retrospectively evaluated
12 ICU patients with MODS treated with argatroban.
All patients had developed thrombocytopenia after
heparin exposure and had argatroban treatment initiated
for suspected HIT whether the diagnosis was ultimately
confirmed. The patients in this series were critically ill
at the time of argatroban initiation (APACHE II score,
26.7 ± 7.8; SAPS II score, 61.5 ± 16.3) and were treated
for MODS. All patients had a platelet count <100,000/μl
(mean platelet count at the time of starting argatroban
anticoagulation, 46,000 ± 30,310/μl). The overall clinical
status of our patient population was probably more cri-
tical compared with those reported previously. Our
patients were treated with a median argatroban starting
dose of 0.32 ± 0.25 μg/kg/min. Further dose reduction
was needed in 50% of the patients. The final required
median argatroban dose was 0.24 ± 0.16 μg/kg/min,
representing one eighth of the usually recommended
dose. Desired levels of anticoagulation were promptly
achieved in all patients.
Compared with previous data, the argatroban dose we
applied in our MODS patients was markedly lower than
the previously suggested dose for ICU patients, probably
reflecting the degree of illness in our patients; likely a
tendency existed toward targeting the lower end of the
therapeutic aPTT range in these very ill patients.
For example, one recent study investigated argatroban
treatment in critically ill ICU patients with HIT II and
the necessity for continuous renal-replacement therapy
[16]. In this study, Link et al. [16] developed recommen-
dations for argatroban dosing during continuous renal-
replacement therapy: They used an initial argatroban
bolus of 100 μg/kg followed by continuous infusion of
argatroban. In contrast, no bolus of argatroban was used
in our study to avoid a peak response of anticoagulation
with the risk of bleeding complications. The average
rate of argatroban in the study of Link et al. was higher
compared with our study (0.70 μg/kg/min versus
0.24 μg/kg/min). Although both studies investigate arga-
troban treatment in critically ill patients, our study
population of patients with MODS is clearly different
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contrast to our study, Link et al. included only patients
receiving continuous renal-replacement therapy. Arga-
troban was applied into the extracorporeal circulation
(prefilter injection/infusion). Furthermore, none of the
critically ill patients included in the Link study had a
previous history of liver disease. Mean SAPS-II score
was lower in this study population compared with that
in our study (45 versus 61.5 points).
In general, in critically ill patients with MODS thera-
peutic interventions are a special challenge. Multifacto-
rial changes in drug disposition and effect occur in
these patients, resulting from drug/patient, drug/disease,
and drug/drug interactions [33]. In particular, the liver
as the primary site of biotransformation can be influ-
enced manifestly, and hepatic impairment is associated
with decreased systemic clearance and increased elimi-
nation half-life of argatroban [11,22].
Conclusions
The results of our study suggest that patients with
MODS and HIT can be effectively treated by using arga-
troban anticoagulation. A high index of suspicion is
required in diagnosing HIT in these complex patients.
However, in critically ill patients with MODS, the dosing
of argatroban has to be adjusted. These data do not sup-
port the current recommendation of 0.5 to 1.0 μg/kg/min
in patients with critical illness as a reasonable, conserva-
tive initial dosage of argatroban. To avoid excessive antic-
oagulation and bleeding complications, argatroban
should be initiated at a markedly reduced dose of about
one tenth to one eighth of the recommended 2 μg/kg/
min in ICU patients with MODS. Because achievement
of steady-state anticoagulation will be delayed in this
patient population, aPTT must be checked at close inter-
vals after drug initiation or dose change to ensure that
the desired level of anticoagulation is achieved. Further
studies are needed to investigate argatroban elimination
and dosage adjustments for ICU patients with MODS.
Key messages
￿ Patients with MODS and HIT can be effectively
treated by using argatroban anticoagulation.
￿ In critically ill patients with MODS, the dosing of
argatroban has to be adjusted.
￿ To avoid excessive anticoagulation and bleeding
complications, argatroban should be initiated at a
markedly reduced dose.
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